Is FDMT or GLUE more undervalued in 2026?

CirclFi compares 4D Molecular Therapeutics, Inc. (FDMT) and Monte Rosa Therapeutics, Inc. (GLUE) using 13 institutional-grade valuation models. FDMT has a Quality of Company score of 7.1/10 while GLUE scores 5.2/10.

Which is a better buy — FDMT or GLUE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do FDMT and GLUE valuations compare?

FDMT at $9.91 and GLUE at $19.71 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

FDMT vs GLUE Valuation Comparison 2026 — Intrinsic Value Analysis

FDMT

Biological Products, (No Diagnostic Substances)

4D Molecular Therapeutics, Inc.

Quality

7.1

out of 10

Value Trap

SAFE

Price

$9.91

Last close

Models

9/13

Active

GLUE

Biological Products, (No Diagnostic Substances)

Monte Rosa Therapeutics, Inc.

Quality

5.2

out of 10

Value Trap

SAFE

Price

$19.71

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	FDMT Fair Value	FDMT Upside	GLUE Fair Value	GLUE Upside
Bayesian DCF	Intrinsic	$2.84	-71.4%	$5.96	-69.8%
Earnings Power Value	Intrinsic	—	—	$3.72	-80.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$8.24	-16.8%	$4.13	-79.0%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for FDMT vs GLUE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

FDMT vs GLUE — Which Stock Is More Undervalued?

FDMT scores higher with a 7.1/10 quality rating vs GLUE's 5.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing 4D Molecular Therapeutics, Inc. (FDMT) and Monte Rosa Therapeutics, Inc. (GLUE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

FDMT currently trades at $9.91 with a QOC of 7.1/10, while GLUE trades at $19.71 with a QOC of 5.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).